were performed using low-osmolality agents.'2 Although these estimates do not include the costs of treating adverse reactions, other studies have shown that expense to be small compared with the cost of low-osmolality agents. 13, 14 A contrast agent's performance should be judged by whether it enables a physician to perform an adequate diagnostic examination or therapeutic intervention without causing a clinically important adverse event (one that jeopardizes the patient or requires abbreviation of the procedure, reducing the amount of information derived from the examination). To justify their high cost, low-osmolality agents should either achieve a meaningful reduction in the frequency of clinically important contrast agent-related adverse events or enhance the ability to conduct a complete examination.
If low-osmolality agents do provide safety benefits, it is important to determine whether these benefits exist for all patients or only for an identifiable subgroup of patients. If the benefit is confined to a subgroup, it may be possible to develop a mechanism for selective rather than universal use of low-osmolality agents.
To address these issues, we conducted a prospective, double-blind, randomized trial comparing low-and high-osmolality contrast agents in a study population that included 96% of all patients undergoing diagnostic cardiac angiography. The goal was to determine the frequency of clinically important contrast agent-related adverse events in this patient population and to relate the frequencies of these events to patient characteristics and the contrast agent used. Specifically, we sought to (1) assess the association between contrast agent type and the frequency of clinically important contrast agent-related adverse events, (2) characterize the clinical and demographic factors associated with these events, and (3), if justified, identify patient subgroups at high and low risk of incurring these events.
Methods Study Design and Patient Population
A randomized, double-blind clinical trial comparing lowwith high-osmolality contrast agents was conducted among patients undergoing diagnostic cardiac angiography at the Hospital of the University of Pennsylvania between December 15, 1989 , and March 7, 1991 . Patients undergoing therapeutic catheterization procedures were excluded. All diagnostic cardiac angiography patients were eligible for randomization to either a low-or high-osmolality contrast agent unless they met one of the six exclusion criteria that identified a small, extremely ill, and high-risk subset of the population. These were (1) documented prior major reaction to contrast agent, including circulatory collapse, bronchospasm, or laryngeal edema; (2) requirement for circulatory support with either intravenous pressors or a mechanical device; (3) left ventricular end-diastolic pressure >40 mm Hg, pulmonary capillary wedge pressure >30 mm Hg, or arteriovenous oxygen difference >7.0 vol%; (4) ongoing acute myocardial infarction or persistent severe chest pain accompanied by persistent episodes of ST segment depression >0.3 mV; (5) left main coronary diameter stenosis >50% and need to perform left ventriculography; or (6) estimated aortic valve area <0.5 cm2, pulmonary capillary wedge pressure >20 mm Hg, and need to perform left ventriculography. Study eligibility was determined by the senior angiographer before initiation of the procedure.
By protocol at our institution, all eligible patients would have received a high-osmolality agent if the trial were not in progress. Thus, because all patients in the trial received either the contrast agent they would have received in the absence of the trial or a contrast agent generally agreed to be at least as safe and effective as the standard high-osmolality agent, no special consent form was required by the institutional review board. All patients provided informed consent to have data abstracted from their hospital record for research purposes.
Cardiac Catheterization Procedure
A study coordinator used a computer-derived randomnumber algorithm to assign each patient to receive either iohexol (Omnipaque 350), a nonionic low-osmolality agent, or diatrizoate (Hypaque 76), a high-osmolality agent, and delivered the appropriate contrast agent to the procedure room. All contrast agents were packaged in identical foil-wrapped bottles. Hypaque 76 was selected as the diatrizoate preparation because its formulation, like The associations of several variables with clinically important end point events not adjusted for contrast agent effect and the unadjusted effect of contrast agent assignment were evaluated using odds ratios and corresponding 95% confidence intervals. Logistic regression was used to derive estimates of overall contrast agent effect adjusted for variables independently associated with the end point events and for imbalance in random assignment of patients to groups. Main effects and interaction models were developed and evaluated. Odds ratios and their 95% confidence intervals were calculated for each model variable.
Sensitivity analyses were carried out excluding the patients who received either open-label iohexol for internal mammary artery injections or Renografin 76. In addition, the data were analyzed on the basis of the actual contrast agent received (rather than intention to treat), with the 37 patients who had been converted to low-osmolality contrast agent before receiving contrast classified to the contrast agent actually received rather than that assigned. The results of these analyses were virtually identical to the intention-to-treat analyses that are reported here.
Variables were divided into two categories: precontrast and postcontrast. The values of precontrast variables, such as patient age, NYHA functional class, and left ventricular end-diastolic pressure, are known before contrast agent administration, whereas the values of postcontrast variables, such as the number of diseased coronary vessels and left ventricular ejection fraction, become known only after angiography. Linear logistic regression analysis was used to develop two predictive models of end point events: a postcontrast model using all variables and a precontrast model using only precontrast variables. The outcome of the precontrast model can be used to guide contrast agent selection, whereas the outcome of the postcontrast model furnishes the fullest explanation of the associations with end point events.
The precontrast model was used to estimate each patient's likelihood of experiencing an end point event based on the values of the variables in the model. The entire patient population was then stratified by degree of risk for an end point event assuming use of a low-osmolality contrast agent, organized into risk quartiles, and segregated by contrast agent group. The actual frequency of events for each contrast agent group in each risk quartile was then compared. This approach to risk stratification assesses the effect of contrast agent in subpopulations at different degrees of risk of an event.22 23 
Results

Patient Population
During the study period, the cardiac catheterization laboratory performed 2245 diagnostic angiographic procedures (Table 2) . Of these, 2166 (96%) patients were successfully randomized to iohexol (n=1077) or diatri- (Table 3) . The study population experienced a total of 78 (3.6%) end point events (6 major events, 34 clinically important events, 33 procedure abbreviations, and 5 conversions to open-label contrast after contrast agent administration). There were more end point events in the diatrizoate group than in the iohexol group (4.6% versus 2.6%; unadjusted odds ratio, 1.80; 95% confidence interval, 1.1-2.9; P=.01). There were no deaths.
Associations Among Patient Characteristics, Contrast Agent, and End Point Events
The bivariate associations (independent of contrast agent assignment) between selected patient characteristics and clinically important end point events and between contrast agent and end point events are listed in Table 4 . The odds ratios and 95% confidence intervals for contrast agent effect on end point events are displayed in Fig 1. These include the unadjusted effect for the entire patient population, the effect modification by individual patient characteristics, logistic model adjustment effects, and the effects in high-and low-risk subgroups as determined by a risk classification algorithm presented later.
Patients experiencing an end point event were older (P<.001), had a greater frequency of a previous reaction to contrast agent (P<.0001), and had a higher NYHA functional class (P<.01). They also had a higher left ventricular end-diastolic pressure (P<.0001), a greater arteriovenous oxygen difference (P=.04), and more severe coronary artery disease (P<.0001).
Examination of the effect of contrast agent assignment on end point events (Fig 1) indicated excluded from the variable list. This analysis, which included all except five patients, yielded a virtually identical odds ratio for contrast agent effect (Fig 1) , indicating that the missing observations did not bias the findings of the logistic adjustment models. In the pre-contrast agent model, the exclusion of the extent of coronary artery disease (which is not known until after angiography is performed) strengthened the associations with end point events for history of previous contrast agent reaction, age, NYHA functional class, baseline left ventricular end-diastolic pressure, and contrast agent assignment. In the pre-contrast agent model, the odds ratio for an end point event attributable to high-osmolality contrast agent was 1.66 (95% confidence interval, 1.02-2.71; P=.04).
Prediction of End Point Events
The pre-contrast agent model was used to stratify the patients into quartiles of risk for an event, and the actual frequency of events in each quartile was tabulated2223 (Fig 2) . In the lowest three quartiles of risk, the likelihood of an end point event was small (25 of 1519, or 1.6%). Consequently, the three low-risk quartiles were combined. In this combined group, the difference between the two contrast agent groups in end point event frequency was not statistically significant (odds ratio, 1.53; 95% confidence interval, 0.68-3.43; P=.30).
In contrast, the frequency of end point events in the highest-risk quartile was six times greater (52 of 550, or 9.5%) than that in the combined three low-risk quartiles. Two thirds of the end point events occurred in the high-risk quartile, and the odds ratio for an end point event attributable to high-osmolality contrast agent was 1.90 (95% confidence interval, 1 Table of odds ratios and 95% confidence intervals for effect of contrast agent assignment on the frequency of end point events for the entire study population, for subgroups identified by selected clinical characteristics, for the entire population after adjustment by the two multivariable logistic models, and for the low-and high-risk subgroups described in the text. An odds ratio significantly >1.0 for a particular patient group indicates that the use of iohexol in that group will reduce the frequency of end point events. The effect of iohexol in reducing the frequency of events is more pronounced in subgroups with age >65 years, New York Heart Association functional class 2111, and coronary disease of two or more vessels. When patients are separated by the risk classification algorithm, the effect of iohexol to reduce event frequency is confined to the high-risk group. LVEDP indicates left ventricular end-diastolic pressure; CAD, coronary artery disease.
Low-risk patients had an overall end point event rate of 2.0%, and the end point event rates in the diatrizoate and iohexol groups were similar (2.2% versus 1.8%; odds ratio, 1.23; 95% confidence interval, 0.58-2.60; P=.59) (Fig 3) . High-risk patients had an overall end point event rate of 7.5%, with the event rate in the diatrizoate group being twice that of the iohexol group (9.7% versus 4.9%; odds ratio, 2.09; 95% confidence interval, 1.11-3.91; P=.02).
Discussion
Three parameters must be considered when examining the importance of a low-osmolality contrast agent's potential to facilitate the conduct of an angiographic procedure and to enhance its safety: (1) the severity, or clinical importance, of the adverse events under consideration (many of the adverse events caused by contrast agents are minor and do not affect safety); (2) the odds ratio for events comparing the two contrast agent classes (this indicates the fractional reduction of events that can be achieved by substituting a low-for a high-osmolality contrast agent); and (3) the absolute frequency of these events. If the frequency is small, the number of events prevented by substituting low-osmolality contrast agents will be small compared with the number of procedures performed even if the odds ratio for the contrast agent effect is large.
If scientifically founded, appropriately guided selective use of low-osmolality contrast agents offers the potential to decrease costs without increasing patient risk. However, for such a strategy to be effective, it is necessary to identify a large subgroup of the total patient population in whom low-osmolality agents do not confer a clinically important advantage. Otherwise, either safety will be compromised or the cost savings will be too modest to make the effort worthwhile.
Other studies have explored this issue but have been limited by one or more of three methodological problems: (1) the patient population was a small subset of the total population of patients undergoing cardiac angiography, thus limiting the generalizability of the findings to a comprehensive patient population2,7'8; (2) the definition of an adverse reaction included many reactions that were easily managed and thus were not truly clinically important2 '8,9-24; or (3) With 2166 patients, this study is one of the largest randomized, blinded cardiac angiographic trials reported and thus has greater statistical power to detect 16- adverse events. The patient population is also nearly all inclusive. All patients except the most severely ill 3% of the patients undergoing diagnostic cardiac angiography at our hospital were eligible for entry into the study, and 99.2% of eligible patients were successfully enrolled. Thus, the study's findings can be applied to all except the most severely ill patients undergoing cardiac angiographic procedures. The clinically important end point event -the study's fundamental unit of analysis -was 16-. 14-Ul) z12- Steinberg et a17 identified high-risk patients as those with unstable angina or >60 years old. This definition included 61% of the patients in their study group, which, in turn, was drawn from only 26% of their total population undergoing angiography. Barrett et al,10 in a study that used a calcium-binding high-osmolality contrast agent, identified heart failure, myocardial infarction within the previous 2 weeks, unstable angina, previous coronary artery bypass grafting, known threevessel coronary disease, and advanced valvular disease as predictors of high risk. These criteria placed 39% of their population in the high-risk group, which was drawn from 80% of their total population.
Our observations extend those of Steinberg et al and Barrett et al. Our high-risk criteria are more selective, classifying less than one third of the population as high risk. They are also more generalizable, as more than 97% of all patients undergoing diagnostic angiography were entered into our study. Moreover, our data clearly demonstrate that in the lower-risk 75% of patients, non-calcium-binding high-osmolality contrast agents can be used with safety and effectiveness equal to that of low-osmolality agents. On the other hand, our data show that in the high-risk population, low-osmolality agents provide a clear safety and effectiveness benefit.
The development of a strategy for the selective use of low-osmolality contrast agents is simplified by the fact that the low-risk group, as defined by our algorithm, is large; has a small frequency of clinically important end point events; and does not have a significant odds ratio for contrast agent effect. For illustrative purposes, we examined the effect on safety and cost for contrast agent of applying the algorithm to contrast agent selection for a hypothetical group of 1000 patients with the same distribution of characteristics as our study population. Despite this study's size, its statistical power to detect a difference between specified subgroups is modest, and the inherent limitations of subgroup analyses are well known.29-3' Although we have attempted to constrain the impact of random-chance phenomena by a priori choice of the clinically relevant variables to include in the models, a larger sample size might have identified trends in other subgroups. However, trends detectable only with greater statistical power are unlikely to be pragmatically important in the context of the economic considerations that influence contrast agent selection.
Caution should be used in generalizing these findings to all intravascular contrast agent use (intravenous and intra-arterial in other vascular beds). The highly monitored environment of the cardiac catheterization laboratory is ideal for administering contrast agent. The patient's clinical condition is fully characterized using ECG and intravascular hemodynamic monitoring. This enables physicians to recognize and to react to clinical deterioration before it might otherwise be evident. It is not clear whether the same degree of safety can be achieved in other types of radiological facilities.
Our analysis is based on the premise that clinically important events are those that jeopardize the patient or significantly affect procedure conduct (eg, result in study termination before all required data are obtained). Im This study quantifies the trade-offs among safety, effectiveness, and cost of selective versus universal use of low-osmolality contrast agents. Our predictive model demonstrates that although low-osmolality agents provide a safety and effectiveness benefit for high-risk patients, in low-risk patients, high-osmolality agents can be used with a safety and effectiveness equal to that of low-osmolality agents. If validated, this model would provide a practical strategy for selective use of lowosmolality contrast agents, yielding a degree of safety equal to the exclusive use of low-osmolality agents at a substantially reduced cost. This strategy requires accepting a greater frequency of minor adverse reactions in the low-risk patients who would receive high-osmolality agents. The threshold for accepting this costeffectiveness trade-off must be determined by societal values weighing convenience against cost.
